Figure 3.
MSCE116K promotes growth of normal and neoplastic T cells. (A) MSCwt inhibited cell growth in normal CD4+ T cells stimulated with anti-CD3/CD28. Growth inhibition was completely reversed by MSCE116K with an additional trend toward increased growth over baseline control. (B) Western blot of musculin expression in cells from the experiment shown in (A). (C) MSCwt inhibited cell cycle progression via G1 arrest; G1 arrest was reversed by MSCE116K. (D) Coexpression of normal CD4+ T cells with MSCwt and MSCE116K rescued cells from the growth inhibition induced by MSCwt alone. Cells were flow sorted for ZsGreen and mCherry double positivity prior to evaluation. Representative results from 3 independent experiments. The Student t test was used to compare results. (E) GSEA of genes differentially expressed in CD4+ T cells overexpressing MSCwt vs control-transduced cells showed depletion of genes encoding MYC and E2F targets. (F) Overexpression of MSCwt inhibited growth in MSClow Karpas 299 cells, whereas overexpression of MSCE116K promoted growth. Data show growth relative to vector control in a competitive growth assay; error bars reflect 3 independent experiments. (G) Small interfering RNA (siRNA) knockdown of MSC increased cell growth in MSChigh Mac-1 cells relative to cells treated with a control siRNA. Data reflect 3 independent experiments. The Student t test was used to compare results. (H) Western blot of musculin expression in cells from the experiment shown in (G). *P < .05, MSCwt vs MSCE116K.